Wells Fargo raised the firm’s price target on iRhythm (IRTC) to $225 from $220 and keeps an Overweight rating on the shares. The firm notes the company pre-announced that 2025 revenue will be above the high end of its prior guidance and guided to 2026 revenue growth of 17%-18%, above prior outlook of 16%-18%.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Irhythm Technologies: Durable Growth, Margin Expansion, and Beat-and-Raise Potential Support Buy Rating
- iRhythm sees FY25 revenue exceeding $740M, consensus $737.99M
- iRhythm sees FY26 revenue $870M-$880M, consensus $862.68M
- iRhythm price target raised to $211 from $202 at Goldman Sachs
- Evercore ISI upgrades four, downgrades six in MedTech and Tools